右心床旁超声改善低危急性心衰风险分层:REED-AHF前瞻性研究
该前瞻性研究在两家城市学术急诊科纳入120例急性心衰患者,最终84例符合纳入和诊断裁定标准,在首次静脉利尿、正压通气或硝酸甘油前或<1小时内行床旁超声。以TAPSE≥17 mm为主要指标,联合已验证的STRATIFY临床决策工具构建完整模型,与仅用STRATIFY的简化模型比较。结果显示TAPSE≥17 mm联合STRATIFY较单用STRATIFY改善预测(aOR 0.24,95%CI 0.06-0.91;NRIcont 0.71,95%CI 0.22-1.19),在比标准诊疗更严格的风险阈值下特异度提高6%~32%(p<0.05)且未额外漏诊事件。
要点
- 在急诊急性心衰患者中,STRATIFY评分联合TAPSE≥17 mm较单用STRATIFY改善风险预测(aOR 0.24,95%CI 0.06-0.91;NRIcont 0.71,95%CI 0.22-1.19)。
- 在比标准诊疗更严格的风险阈值下,加测TAPSE≥17 mm使特异度提高6%~32%(p<0.05),且未额外漏诊事件。
- 发生主要结局的患者STRATIFY评分高于无事件者(233 vs. 212,p=0.009)。
- 五个右心参数(TAPSE、TAPSE/PASP、TAPSE/RVDD、RV-FAC、fwRVLS)在调整STRATIFY后改善预测(p<0.05),而六个左心参数均未改善。
- 右心参数的变量重要性高于左心参数。
适用人群与场景
- 两家城市学术急诊科前瞻性纳入的急性心衰患者,最终84/120例符合纳入和诊断裁定标准。
- 排除ST段抬高型心肌梗死和心源性休克患者。
- 床旁超声在首次静脉利尿、正压通气或硝酸甘油之前或之后<1小时内完成。
诊断标准与关键阈值
- 急性心衰诊断由双盲专家复核裁定。
- TAPSE采用预先设定的界值≥17 mm作为主要指标。
- STRATIFY为已验证的临床决策工具,预测急诊急性心衰患者30天内死亡/心肺复苏、机械心脏支持、插管、新发/急诊透析、急性心肌梗死或冠状动脉血运重建。
研究设计与关键结果
- 研究类型为前瞻性研究,最终纳入84例符合纳入和诊断裁定标准的患者,来自两家城市学术急诊科。
- 主要结局发生率为19%;发生主要结局的患者STRATIFY评分高于无事件者(233 vs. 212,p=0.009)。
- 五个右心参数(TAPSE、TAPSE/PASP、TAPSE/RVDD、RV-FAC、fwRVLS)在调整STRATIFY后改善预测(p<0.05),六个左心参数均未改善。
- TAPSE≥17 mm联合STRATIFY较单用STRATIFY改善预测(aOR 0.24,95%CI 0.06-0.91;NRIcont 0.71,95%CI 0.22-1.19)。
- 在比标准诊疗更严格的风险阈值下,加测TAPSE≥17 mm使特异度提高6%~32%(p<0.05),且未额外漏诊事件。
- 随机森林分析显示右心参数的变量重要性更高。
证据类型、等级与局限
- 证据类型:前瞻性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在使用已验证的临床决策工具后,TAPSE可提高低危急性心衰患者的检出,支持在更严格风险阈值下识别可考虑门诊治疗的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Validated acute heart failure (AHF) clinical decision instruments (CDI) insufficiently identify low-risk patients meriting consideration of outpatient treatment. While pilot data show that tricuspid annulus plane systolic excursion (TAPSE) is associated with adverse events, no AHF CDI currently incorporates point-of-care echocardiography (POCecho). We evaluated whether TAPSE adds incremental risk stratification value to an existing CDI.
METHODS: Prospectively enrolled patients at two urban-academic EDs had POCechos obtained before or <1 h after first intravenous diuresis, positive pressure ventilation, and/or nitroglycerin. STEMI and cardiogenic shock were excluded. AHF diagnosis was adjudicated by double-blind expert review. TAPSE, with an a priori cutoff of ≥17 mm, was our primary measure. Secondary measures included eight additional right heart and six left heart POCecho parameters. STRATIFY is a validated CDI predicting 30-day death/cardiopulmonary resuscitation, mechanical cardiac support, intubation, new/emergent dialysis, and acute myocardial infarction or coronary revascularization in ED AHF patients. Full (STRATIFY + POCecho variable) and reduced (STRATIFY alone) logistic regression models were fit to calculate adjusted odds ratios (aOR), category-free net reclassification index (NRIcont ), ΔSensitivity (NRIevents ), and ΔSpecificity (NRInonevents ). Random forest assessed variable importance. To benchmark risk prediction to standard of care, ΔSensitivity and ΔSpecificity were evaluated at risk thresholds more conservative/lower than the actual outcome rate in discharged patients.
RESULTS: A total of 84/120 enrolled patients met inclusion and diagnostic adjudication criteria. Nineteen percent experiencing the primary outcome had higher STRATIFY scores compared to those event free (233 vs. 212, p = 0.009). Five right heart (TAPSE, TAPSE/PASP, TAPSE/RVDD, RV-FAC, fwRVLS) and no left heart measures improved prediction (p < 0.05) adjusted for STRATIFY. Right heart measures also had higher variable importance. TAPSE ≥ 17 mm plus STRATIFY improved prediction versus STRATIFY alone (aOR 0.24, 95% confidence interval [CI] 0.06-0.91; NRIcont 0.71, 95% CI 0.22-1.19), and specificity improved by 6%-32% (p < 0.05) at risk thresholds more conservative than the standard-of-care benchmark without missing any additional events.
CONCLUSIONS: TAPSE increased detection of low-risk AHF patients, after use of a validated CDI, at risk thresholds more conservative than standard of care.
参考来源
- Harrison NE, Favot MJ, Gowland L, et al. Point-of-care echocardiography of the right heart improves acute heart failure risk stratification for low-risk patients: The REED-AHF prospective study. Acad Emerg Med. 2022. PMID: 36047646. doi:10.1111/acem.14589
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。